Abstract

Selpercatinib Is a Promising Treatment Option for <i>RET</i>-Mutated Medullary and <i>RET</i> Fusion-Positive Thyroid Cancers

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call